Dr. David Fuentes, MD
Allergy & Immunology (Allergy Physician)
- Medicare participating
At a glance
- Medical school
- University of Texas Medical School at San Antonio (1991)
- Years since graduation
- 35
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 226
Licensed in Texas since 1993, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1991Medical school: University of Texas Medical School at San Antonio
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Allergy Physician primary
TX license J3309 (first issued 1993; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Medicare patients and services
- Medicare patients, 2024
- 226
- Services billed
- 4,290
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Test for allergy using allergenic extract | 2,214 | 42 |
| Professional service for preparation and provision of 1 or more antigens | 919 | 32 |
| Professional service for single injection of allergen | 389 | 26 |
| Established patient office or other outpatient visit, 30-39 minutes | 251 | 166 |
| Professional service for multiple injections of allergen | 189 | 12 |
| Established patient office or other outpatient visit, 40-54 minutes | 90 | 74 |
| Test to measure expiratory airflow and volume | 80 | 53 |
| New patient office or other outpatient visit, 45-59 minutes | 52 | 52 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Montelukast Sodium Other prescribers in Boerne, TX | 229 |
| Ipratropium Bromide Other prescribers in Boerne, TX | 177 |
| Trelegy Ellipta (fluticasone/umeclidin/vilanter) Other prescribers in Boerne, TX | 166 |
| Albuterol Sulfate Hfa (albuterol sulfate) Other prescribers in Boerne, TX | 99 |
| Levocetirizine Dihydrochloride Other prescribers in Boerne, TX | 94 |
| Azelastine Hcl Other prescribers in Boerne, TX | 74 |
| Breo Ellipta (fluticasone/vilanterol) Other prescribers in Boerne, TX | 72 |
| Prednisone Other prescribers in Boerne, TX | 56 |
| Cefuroxime (cefuroxime axetil) Other prescribers in Boerne, TX | 55 |
| Fluticasone Propionate Other prescribers in Boerne, TX | 48 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 21 companies reported 67 payments worth $1,859 in total to this clinician.
| AstraZeneca Pharmaceuticals LP | $476 |
|---|---|
| Sanofi-aventis U.S. LLC | $292 |
| Insmed, Inc. | $168 |
| GlaxoSmithKline, LLC. | $157 |
| Csl Behring | $113 |
| Pharming Healthcare, Inc. | $85.42 |
| Ionis Pharmaceuticals, Inc. | $74.96 |
| Genzyme Corporation | $67.30 |
| Food and Beverage | $1,825 |
|---|---|
| Education | $34.00 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Amgen Inc. Aug 20, 2025 | Education in-kind | $34.00 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 36 industry-funded studies in 2025, from 10 companies. The companies reported $3,655,954 in research payments for these studies, mostly to the institutions running them.
- Ph III OLE of Astegolimab in COPD
Genentech, Inc. - Dose Ranging Study of Lunsekimig Compared With Placebo-control in Adult Participants With Moderate-to-severe Asthma
Sanofi US Services Inc. · Completed · NCT06102005 - Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study
Sanofi US Services Inc. · Terminated · NCT06033833 - Ph1c proof of activity study of GDC-6988 in patients with COPD and NCFB
Genentech, Inc. - Long-term Safety and Efficacy Evaluation of Lunsekimig (SAR443765) in Adult Participants With Asthma
Sanofi US Services Inc. · Enrolling by invitation · NCT06609239 - A Phase 2a Randomised Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of AZD4604 Twice Daily for Twelve Weeks in Adult Patients with Moderate-to-Severe Asthma Uncontrolled on Medium-High Dose…
AstraZeneca Pharmaceuticals LP - A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose Ranging Study to Assess the Efficacy and Safety of Rocatinlimab in Adult Subjects With Moderate-to-severe Asthma
Amgen Inc. - Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma
Sanofi US Services Inc. · Active, not recruiting · NCT06676319 - A multicentre, randomized, double-blind, placebo-controlled, dose find
GlaxoSmithKline, LLC. - Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adult Participants with Moderate to Very Severe Chronic Obstructive Pulmon…
AstraZeneca Pharmaceuticals LP
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.